Evgeny N Imyanitov

Summary

Country: Russia

Publications

  1. ncbi Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing
    Anna P Sokolenko
    NN Petrov Institute of Oncology, St, Petersburg, Russia
    Hered Cancer Clin Pract 7:2. 2009
  2. ncbi Exploring the link between MORF4L1 and risk of breast cancer
    Griselda Martrat
    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
    Breast Cancer Res 13:R40. 2011
  3. ncbi Evidence for microsatellite instability in bilateral breast carcinomas
    E N Imyanitov
    Group of Molecular Diagnostics and Laboratory of Pathomorphology, N N Petrov Institute of Oncology, St Petersburg, Russia
    Cancer Lett 154:9-17. 2000
  4. ncbi BRCA1 4153delA founder mutation in Russian ovarian cancer patients
    Nadezhda Yu Krylova
    NN Petrov Institute of Oncology, St, Petersburg, Russia Medical Academy of Postgraduate Studies, St, Petersburg, Russia
    Hered Cancer Clin Pract 4:193-6. 2006
  5. ncbi Molecular-based choice of cancer therapy: realities and expectations
    Evgeny N Imyanitov
    Laboratory of Molecular Oncology, N N Petrov Institute of Oncology, St Petersburg, Russia
    Clin Chim Acta 379:1-13. 2007
  6. ncbi Use of elderly tumor-free subjects as a "supercontrol" for cancer epidemiological studies: pros and cons
    Evgeny N Imyanitov
    Laboratory of Molecular Oncology, N N Petrov Institute of Oncology, Pesochny 2, 197758 St Petersburg, Russia
    Mech Ageing Dev 130:122-7. 2009
  7. ncbi Drug therapy for hereditary cancers
    Evgeny N Imyanitov
    Laboratory of Molecular Oncology, N, N, Petrov Institute of Oncology, St, Petersburg, 197758, Russia
    Hered Cancer Clin Pract 9:5. 2011
  8. ncbi Gene polymorphisms, apoptotic capacity and cancer risk
    Evgeny N Imyanitov
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Hum Genet 125:239-46. 2009
  9. ncbi High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
    Evgeny N Suspitsin
    Laboratory of Molecular Oncology, Petrov Institute of Oncology, St, Petersburg, Russia
    Hered Cancer Clin Pract 7:5. 2009
  10. ncbi CHEK2 1100 delC mutation in Russian ovarian cancer patients
    Nadezhda Yu Krylova
    Medical Academy of Postgraduate Studies, Sankt Petersburg, Russia
    Hered Cancer Clin Pract 5:153-6. 2007

Collaborators

  • Ari Hirvonen
  • Boris Zhivotovsky
  • Antonis C Antoniou
  • Kai Oliver Henrich
  • Ingolf Cascorbi
  • Manfred Schwab
  • Yoshio Miki
  • C Theillet
  • Alexandr V Togo
  • Aglaya G Iyevleva
  • Anna P Sokolenko
  • Evgeny N Suspitsin
  • Ekatherina Sh Kuligina
  • Dmitry E Matsko
  • Vladimir F Semiglazov
  • Konstantin G Buslov
  • Nathalia V Mitiushkina
  • Alexandr O Ivantsov
  • Yulia M Ulybina
  • Vladimir M Moiseyenko
  • Dmitry A Voskresenskiy
  • Peter Devilee
  • Evgeniya V Belogubova
  • Nadezhda Yu Krylova
  • Maxim E Rozanov
  • Elena V Chekmariova
  • Evgeny V Levchenko
  • Kaido P Hanson
  • Elena M Bit-Sava
  • Yulia M Ulibina
  • Natalia V Mitiushkina
  • Cees Cornelisse
  • Svetlana N Abysheva
  • Vladimir A Shutkin
  • Oleg L Chagunava
  • Tatiana V Gorodnova
  • Nathalia Yu Sherina
  • Maria B Karpova
  • Olga S Yatsuk
  • Daria N Ponomariova
  • Olga A Zaitseva
  • Elena A Turkevich
  • Sergey Ya Maximov
  • Oksana S Lobeiko
  • Adel F Urmancheyeva
  • Yulia R Lazareva
  • Griselda Martrat
  • Ekatherina Kuligina
  • Sergey P Kovalenko
  • Igor I Semionov
  • Andrey V Koloskov
  • Natalia Yu Sherina
  • Julia M Ulibina
  • Lev M Berstein
  • Maxim Y Grigoriev
  • Sergey G Kuznetsov
  • Werner Pfeifer
  • Iduna Fichtner
  • Alexey A Larionov
  • Elena V Preobrazhenskaya
  • Georgy D Dolmatov
  • Dmitry V Voskresenskiy
  • Marie Stenmark-Askmalm
  • Kseniya V Shelehova
  • Katherine L Nathanson
  • Mary B Daly
  • Victor Moreno
  • Gaia Roversi
  • Georgia Chenevix-Trench
  • Siranoush Manoukian
  • Conxi Lazaro
  • Barbara Pasini
  • Rosalind Eeles
  • Tuomas Heikkinen
  • Esther M John
  • Ute Hamann
  • Amanda Spurdle
  • Christopher M Maxwell
  • Ramunas Janavicius
  • Feruza A Sabirova
  • Juan Bueren
  • Valery F Klimashevskiy
  • Lesley McGuffog
  • Nina V Efimova
  • Fiona Lalloo
  • Antoine de Pauw
  • Ekatherina S Kuligina
  • Fergus J Couch
  • Eitan Friedman
  • Maria Castella

Detail Information

Publications39

  1. ncbi Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing
    Anna P Sokolenko
    NN Petrov Institute of Oncology, St, Petersburg, Russia
    Hered Cancer Clin Pract 7:2. 2009
    ..Ideally, all family members affected by breast or ovarian tumor disease have to be subjected to the DNA testing, and failure to detect the mutation in any of them calls for the search of the second cancer-associated allele...
  2. ncbi Exploring the link between MORF4L1 and risk of breast cancer
    Griselda Martrat
    Translational Research Laboratory, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research IDIBELL, Gran Via 199, L Hospitalet del Llobregat 08908, Spain
    Breast Cancer Res 13:R40. 2011
    ..To gain deeper insight into this pathway and its influence on cancer risk, we searched for novel components through protein physical interaction screens...
  3. ncbi Evidence for microsatellite instability in bilateral breast carcinomas
    E N Imyanitov
    Group of Molecular Diagnostics and Laboratory of Pathomorphology, N N Petrov Institute of Oncology, St Petersburg, Russia
    Cancer Lett 154:9-17. 2000
    ..Thus an involvement of both RER(+) and borderline MI appears to be a distinct feature of bilateral breast carcinomas compared to unilateral lesions...
  4. ncbi BRCA1 4153delA founder mutation in Russian ovarian cancer patients
    Nadezhda Yu Krylova
    NN Petrov Institute of Oncology, St, Petersburg, Russia Medical Academy of Postgraduate Studies, St, Petersburg, Russia
    Hered Cancer Clin Pract 4:193-6. 2006
    ..1%). Both these carriers were early-onset and had serous carcinomas of grade 3. Thus, our study supports neither the Russian origin of BRCA1 4153delA mutation, nor its selectivity towards ovarian versus breast cancer predisposition...
  5. ncbi Molecular-based choice of cancer therapy: realities and expectations
    Evgeny N Imyanitov
    Laboratory of Molecular Oncology, N N Petrov Institute of Oncology, St Petersburg, Russia
    Clin Chim Acta 379:1-13. 2007
    ....
  6. ncbi Use of elderly tumor-free subjects as a "supercontrol" for cancer epidemiological studies: pros and cons
    Evgeny N Imyanitov
    Laboratory of Molecular Oncology, N N Petrov Institute of Oncology, Pesochny 2, 197758 St Petersburg, Russia
    Mech Ageing Dev 130:122-7. 2009
    ..Comprehensive studies on distribution of cancer-related gene polymorphisms in elderly population remain to be done...
  7. ncbi Drug therapy for hereditary cancers
    Evgeny N Imyanitov
    Laboratory of Molecular Oncology, N, N, Petrov Institute of Oncology, St, Petersburg, 197758, Russia
    Hered Cancer Clin Pract 9:5. 2011
    ..Given the rapidly improving accessibility of DNA analysis, it is foreseen that the potential predictive value of cancer-associated germ-line mutations will be increasingly considered in the future studies...
  8. ncbi Gene polymorphisms, apoptotic capacity and cancer risk
    Evgeny N Imyanitov
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Hum Genet 125:239-46. 2009
    ..Systematic analysis of cancer-predisposing relevance of other apoptotic gene SNPs remains to be done...
  9. ncbi High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients
    Evgeny N Suspitsin
    Laboratory of Molecular Oncology, Petrov Institute of Oncology, St, Petersburg, Russia
    Hered Cancer Clin Pract 7:5. 2009
    ..Taken together with literature data, this study does not support the contribution of CHEK2 in OC risk, while the role of NBS1 heterozygosity may require further clarification...
  10. ncbi CHEK2 1100 delC mutation in Russian ovarian cancer patients
    Nadezhda Yu Krylova
    Medical Academy of Postgraduate Studies, Sankt Petersburg, Russia
    Hered Cancer Clin Pract 5:153-6. 2007
    ....
  11. ncbi Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?
    Evgeny N Imyanitov
    Petrov Institute of Oncology, Pesochny 2, 197758, St Petersburg, Russia
    Hered Cancer Clin Pract 7:8. 2009
    ....
  12. ncbi Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas
    Evgeny N Imyanitov
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Int J Cancer 100:557-64. 2002
    ..014). Overall, our data suggest that sharing natural histories of the disease, which is more evident in synchronous and/or premenopausal forms of biBC, may result in a similarity of molecular portraits in bilateral breast tumors...
  13. ncbi Improved reliability of allele-specific PCR
    E N Imyanitov
    Group of Molecular Diagnostics, N.N. Petrov Institute of Oncology, St Petersburg, Russia
    Biotechniques 33:484, 486, 488 passim. 2002
  14. ncbi Molecular pathogenesis of bilateral breast cancer
    Evgeny N Imyanitov
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Cancer Lett 191:1-7. 2003
    ..Further research on the biBC molecular pathogenesis may significantly contribute to the general understanding of the process of malignant transformation...
  15. ncbi Evidence for depletion of CASP5 Ala90Thr heterozygous genotype in aged subjects
    Yulia M Ulybina
    N N Petrov Institute of Oncology, Pesochny 2, St Petersburg, Russia
    Exp Gerontol 45:726-9. 2010
    ..Here we present a distinct situation, where the combination of alternative alleles (i.e., heterozygosity) appears to be unfavorable as compared to the homozygous carriership of either gene variant...
  16. ncbi Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia
    Anna P Sokolenko
    N N Petrov Institute of Oncology, Pesochny 2, St Petersburg 197758, Russia
    Fam Cancer 6:281-6. 2007
    ..3%) patient each. No cases with BRCA1 300T>G (C61G) mutation was identified. The obtained data suggest that a significant fraction of hereditary BC cases in Russia can be diagnosed using only a limited number of simple PCR tests...
  17. ncbi 'Comparison of extremes' approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility
    Evgeniya V Belogubova
    Group of Molecular Diagnostics, N N Petrov Institute of Oncology, Pesochny 2, St Petersburg 197758, Russian Federation
    Cancer Lett 221:177-83. 2005
    ....
  18. ncbi CHEK2 1100delC mutation is frequent among Russian breast cancer patients
    Elena V Chekmariova
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Breast Cancer Res Treat 100:99-102. 2006
    ....
  19. ncbi Non-founder BRCA1 mutations in Russian breast cancer patients
    Aglaya G Iyevleva
    N N Petrov Institute of Oncology, St Petersburg 197758, Russia
    Cancer Lett 298:258-63. 2010
    ..We conclude that the non-founder mutations constitute the minority of BRCA1 defects in Russia...
  20. ncbi High frequency of BRCA1 5382insC mutation in Russian breast cancer patients
    Anna P Sokolenko
    Molecular Oncology Department, N N Petrov Institute of Oncology, Pesochny 2, St Petersburg 197758, Russia
    Eur J Cancer 42:1380-4. 2006
    ..The presented data confirm a noticeable contribution of BRCA1 5382insC mutation in BC development in Russia, that may justify an extended BRCA1 5382insC testing within this population...
  21. ncbi High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma
    Vladimir M Moiseyenko
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Onkologie 33:231-8. 2010
    ..The experience of the use of this EGFR tyrosine kinase inhibitor (TKI) in non-Asian subjects remains limited...
  22. ncbi NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia
    Konstantin G Buslov
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Int J Cancer 114:585-9. 2005
    ..In 2 of these tumors, the loss involved the mutant NBS1-allele. Overall, our data suggest that the NBS1 657del5 allele may contribute only to a limited fraction of breast cancer cases in Russia...
  23. ncbi Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects
    Evgeniya V Belogubova
    Group of Molecular Diagnostics, N N Petrov Institute of Oncology, Pesochny 2, 197758 St Petersburg, Russia
    J Cancer Res Clin Oncol 132:327-31. 2006
    ..This study was aimed to validate whether the CYP1A1-C (3801) (CYP1A1*2) allele has an unfavorable significance alone and/or in combination with the GSTM1 deficiency...
  24. ncbi Microsatellite instability analysis of bilateral breast tumors suggests treatment-related origin of some contralateral malignancies
    Ekatherina Sh Kuligina
    Laboratory Molecular Oncology, N N Petrov Institute of Oncology, Pesochny 2, St Petersburg, 197758, Russia
    J Cancer Res Clin Oncol 133:57-64. 2007
    ..The present study was designed to examine this unexpected phenomenon in more detail...
  25. ncbi Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer
    Yulia M Ulybina
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Cancer Lett 278:183-91. 2009
    ..92-1.50), p=0.21; OR=1.19 (95% CI: 0.95-1.51), p=0.14, respectively), the obtained data indicate that Casp5, Casp8 and DR4 gene polymorphisms may deserve consideration in large-scale case-control studies of LC risk modifiers...
  26. ncbi Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases
    Evgeny V Levchenko
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Onkologie 32:674-7. 2009
    ..Non-small cell lung carcinomas (NSCLC) carrying a mutation in the epidermal growth factor receptor (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib...
  27. ncbi Measurement of DPD and TS transcripts aimed to predict clinical benefit from fluoropyrimidines: confirmation of the trend in Russian colorectal cancer series and caution regarding the gene referees
    Aglaya G Iyevleva
    N N Petrov Institute of Oncology, St Petersburg, Russia
    Onkologie 30:295-300. 2007
    ..Measurement of intratumoral expression of dihydropyrimidine dehydrogenase (DPD) and thymidylate synthase (TS) may have some value in predicting the response to fluoropyrimidine-containing therapy...
  28. ncbi Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias
    Evgeny N Suspitsin
    Laboratory of Molecular Oncology, N N Petrov Institute of Oncology, St Petersburg, Russia
    Int J Cancer 120:297-302. 2007
    ....
  29. ncbi A novel approach for assessment of cancer predisposing roles of GSTM1 and GSTT1 genes: use of putatively cancer resistant elderly tumor-free smokers as the referents
    Evgeniya V Belogubova
    Group of Molecular Diagnostics, N N Petrov Institute of Oncology, Pesochny 2, 197758, St Petersburg 197758, Russia
    Lung Cancer 43:259-66. 2004
    ....
  30. ncbi Distribution of coding apoptotic gene polymorphisms in women with extreme phenotypes of breast cancer predisposition and tolerance
    Yulia M Ulybina
    NN Petrov Institute of Oncology, St Petersburg, Russia
    Tumori 97:248-51. 2011
    ..Comparison of subjects with extreme phenotypes of cancer susceptibility and tolerance allows to detect low-penetrance gene-disease interactions with a relatively small study size...
  31. ncbi High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia
    Anna P Sokolenko
    N N Petrov Institute of Oncology, St Petersburg 197758, Russia St Petersburg Pediatric Medical Academy, St Petersburg 194100, Russia
    Int J Cancer 130:2867-73. 2012
    ..15/1376 (1.1%), p = 0.64). None of the BLM-associated BC exhibited somatic loss of heterozygosity at the BLM gene locus. This study demonstrates that BLM Q548X allele is recurrent in Slavic subjects and may be associated with BC risk...
  32. ncbi KIT mutations in Russian patients with mucosal melanoma
    Svetlana N Abysheva
    Laboratory of Molecular Oncology, N N Petrov Institute of Oncology, St Petersburg Pediatric Medical Academy, St Petersburg, Russia
    Melanoma Res 21:555-9. 2011
    ..One tumor harbored somatically acquired silent nucleotide substitution c.1383A>G (T461T). This study adds to the evidence that a substantial portion of MMs carry a therapeutically relevant mutation in the KIT oncogene...
  33. ncbi Searching for cancer-associated gene polymorphisms: promises and obstacles
    Evgeny N Imyanitov
    Group of Molecular Diagnostics, N N Petrov Institute of Oncology, St Petersburg 197758, Russia
    Cancer Lett 204:3-14. 2004
    ..It is expected that the increasing capacities of available DNA collections, coupled with the rapid development of high-throughput genotyping technologies, will vastly accelerate the research on polygenic cancer susceptibility...
  34. ncbi CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?
    Lev M Berstein
    Laboratory of Oncoendocrinology, Prof N N Petrov Research Institute of Oncology, Pesochny 2, St Petersburg, Russia
    Cancer Lett 180:47-53. 2002
    ..A1/A1 CYP17 variant may be associated with untraditional (non-steroidal) pathways that calls for corresponding preventive measures in high-risk groups...
  35. ncbi Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier
    Evgeny N Suspitsin
    Laboratory of Molecular Oncology, N N Petrov Institute of Oncology, Pesochny 2, St Petersburg, Russia
    Breast Cancer 18:137-40. 2011
    ..This report exemplifies that even very uncommon breast tumor types may develop through biallelic inactivation of BRCA1 gene, that has to be considered in the genetic testing settings...
  36. ncbi EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: a case report
    Aglaya G Iyevleva
    NN Petrov Institute of Oncology, St Petersburg, Russia
    Urol Oncol 27:548-50. 2009
    ..This case report suggests that kidney tumors have to be investigated more closely with respect to the occurrence of TKI-sensitizing EGFR mutations...
  37. ncbi Evaluating cancer epidemiologic risk factors using multiple primary malignancies
    Ekatherina Kuligina
    N N Petrov Institute of Oncology, Russian Federation, St Petersburg, Russia
    Epidemiology 21:366-72. 2010
    ..We explore these assumptions theoretically and empirically using published data from breast cancer studies involving bilateral breast cancer...
  38. ncbi High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas
    Aglaya G Iyevleva
    Laboratory of Molecular Oncology, N N Petrov Institute of Oncology, Pesochny 2, 197758, St Petersburg, Russia
    Breast Cancer Res Treat 131:1049-59. 2012
    ..004). This study suggests that bilateral breast tumors have somewhat distinct pattern of molecular events as compared to the unilateral disease...
  39. ncbi Expression of caspase-3 and -7 does not correlate with the extent of apoptosis in primary breast carcinomas
    Maxim Y Grigoriev
    NN Petrov Institute of Oncology, St. Petersburg 197758, Russia
    Cell Cycle 1:337-42. 2002
    ..009). Thus, these findings indicate a general dysregulation of spontaneous apoptosis in primary breast tumors...